[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453234":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":66,"collaborators":26,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":26,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Washington State University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(CM+TAU) Contingency Management + Treatment as Usual","EXPERIMENTAL","Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. Participants in CM+TAU will receive reinforcement for submitting urine samples that test negative for recent alcohol use.",[13],"Behavioral: Contingency Management",{"label":15,"type":16,"description":17,"interventionNames":18},"(NC+TAU) No Contingency + Treatment as Usual","ACTIVE_COMPARATOR","Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. NC+TAU will receive reinforcement for submitting any urine sample, regardless of test results.",[19],"Behavioral: Non-contingent control",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Contingency Management","Incentives for submitting negative-alcohol urine samples",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Non-contingent control","Incentives for submitting urine samples",[15],[32],{"name":33,"affiliation":5,"role":34},"Sterling M McPherson, PhD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Abigail Bowen, MS","CONTACT","(425) 736-1354","abigail.bowen@wsu.edu",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Sterling McPherson, PhD","(509) 324-7459","smcpherson05@wsu.edu",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Spokane","Washington","99202","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-117.42908,47.65966,{"lat":57,"lon":56},[60,62],{"name":61,"role":38,"phone":39,"phoneExt":26,"email":40},"Abigail L Bowen, MS",{"name":63,"role":38,"phone":64,"phoneExt":26,"email":65},"Serena M McPherson, BA","(509) 590-7689","s.mcpherson@wsu.edu",{"type":34,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Sterling McPherson","Professor","100453234","phase-2-pharmaceutically-enhanced-reinforcement-for-reduced-alcohol-and-smoking-100453234",false,"NCT05181891","Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking","PERRAS","Inclusion Criteria:\n\n1. 4 or more standard drinks on the same occasion for women (5 or more standard drinks on the same occasion for men) on at least 4 occasions in the prior 30 days\n2. Seeking AUD treatment\n3. Seeking smoking cessation treatment\n4. Aged 18+ years\n5. DSM-5 diagnosis of AUD\n6. Currently smoking daily according to PhenX Smoking Status (100 or more lifetime cigarettes plus current daily smoking)\n7. Ability to read and speak English\n8. Ability to provide written informed consent\n9. Breath alcohol of 0.00 during informed consent\n10. Provision of at least 1 EtG-positive urine test at any time during the induction period and at least one COT-positive urine test at any time during the induction period; and\n11. Attended at least 4 of 6 possible visits during the induction period.\n\nExclusion Criteria:\n\n1. Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal\n2. Currently receiving any pharmacotherapy for alcohol\n3. Currently receiving any pharmacotherapy for smoking\n4. No suicide attempt in the last 20 years and\n5. Any other medical (discernable by initial blood tests) or psychiatric condition that Drs. Layton or Rodin determine would compromise safe participation.",true,"ALL","18 Years",{"count":80,"type":81},205,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.",[87,88],"Alcohol Use Disorder (AUD)","Nicotine Use Disorder",[90,23,91,92,88],"Alcohol Use Disorder","Incentives for Sobriety","Varenicline","2026-06-30",{"date":95,"type":96},"2026-07-02","ACTUAL",{"date":98,"type":96},"2022-07-11",{"date":100,"type":81},"2027-05-01",{"name":5,"class":6},1]